A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2013
At a glance
- Drugs H1IC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Statens Serum Institut
- 10 Jun 2017 Biomarkers information updated
- 13 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.